We investigated the role of mast cells in granuloma-associated angi'/> Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5
首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5
【2h】

Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5

机译:通过控制肥大细胞介质释放抑制肉芽肿相关的血管生成:肥大细胞蛋白酶5的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="enumerated" style="list-style-type:decimal">We investigated the role of mast cells in granuloma-associated angiogenesis in rat by using: (i) a mast cell membrane stabilizer, ketotifen; (ii) a mast cell depleting agent, compound 48/80. Moreover, we focused on the role of chymases, which exhibit proinflammatory and proangiogenic properties by using: (i) chymostatin, an inhibitor of chymase activity; (ii) a specific antisense oligonucleotide (AS-ODN) designed against rat mast cell protease-5 (rMCP-5), the most abundantly expressed chymase in the skin.The formation of granuloma was evaluated, as wet weight, 96 h after the subcutaneous implant of two λ-carrageenin (1%)-soaked sponges on the back of male Wistar rats. Angiogenesis was evaluated as haemoglobin content in the granulomatous tissue and as level of tumour necrosis factor-α (TNF-α) in the exudates.A single injection of ketotifen (1–5–25 mg kg−1 i.p.) significantly reduced granuloma formation by 31.6, 44.6 and 71.9%, and haemoglobin content by 17.0, 35.0 and 66.2%, suggesting that the release of mediator(s) from mast cells modulates the process. Chymostatin (5–10 nmol−1 site−1 day−1) reduced granuloma-associated angiogenesis by 57.3 and 70.0%.RT–PCR analysis showed that rMCP-5 mRNA amounts were significantly reduced by rMCP-5 AS-ODN (1.25–2.5–5.0 nmol site−1) by 69.5, 72.5 and 81.8%. In parallel experiments, rMCP-5 AS-ODN (1.25, 2.5, 5.0 nmol site−1) strongly reduced granuloma weight (26.1, 45.0 and 56.3%) and haemoglobin content (22.2, 50.4, 62.03%), suggesting that the observed effect is mediated through an antisense mechanism.In conclusion, these data suggest that: (i) inhibition of mast cell mediators release may represent a novel strategy to modulate angiogenesis; (ii) among the chymase family, rMCP-5 is a key promoter of angiogenesis in the rat.
机译:class =“ enumerated” style =“ list-style-type:decimal”> <!-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> 我们通过使用以下方法研究了肥大细胞在大鼠肉芽肿相关血管生成中的作用:(i)肥大细胞膜稳定剂酮替芬; (ii)肥大细胞消耗剂,化合物48/80。此外,我们集中于乳糜酶的作用,其通过使用以下物质表现出促炎和促血管生成特性:(i)chymostatin,一种糜蛋白酶活性抑制剂; (ii)针对大鼠肥大细胞蛋白酶5(rMCP-5)设计的特异性反义寡核苷酸(AS-ODN),rMCP-5是皮肤中表达最丰富的糜酶。 评估了肉芽肿的形成,在雄性Wistar大鼠背部皮下植入两个λ-角叉菜胶(1%)浸湿的海绵后96 h,保持湿重。血管生成被评估为肉芽肿组织中的血红蛋白含量和渗出物中的肿瘤坏死因子-α(TNF-α)水平。 单次注射酮替芬(1–5–25 mg kg -1 ip)可使肉芽肿的形成减少31.6%,44.6%和71.9%,使血红蛋白含量减少17.0%,35.0%和66.2%,表明肥大细胞释放介质可调节这一过程。肌凝抑素(5-10nmol -1 -1 day -1 )使肉芽肿相关的血管生成减少了57.3%和70.0%。 RT–PCR分析显示,rMCP-5 AS-ODN(1.25–2.5–5.0 nmol site -1 )使rMCP-5 mRNA的含量显着降低了69.5、72.5和81.8%。 。在平行实验中,rMCP-5 AS-ODN(1.25,2.5,5.0 nmol site -1 )显着降低了肉芽肿的重量(26.1、45.0和56.3%)和血红蛋白含量(22.2、50.4、62.03% 总而言之,这些数据表明:(i)抑制肥大细胞介质的释放可能代表了一种调节血管新生的新策略; (ii)在糜酶家族中,rMCP-5是大鼠血管生成的关键启动子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号